Temporal association between zolpidem medication and the risk of suicide: A 12-year population-based, retrospective cohort study

被引:0
作者
Chul-Hyun Cho
Hee-Jung Jee
Yoon-Ju Nam
Hyonggin An
Leen Kim
Heon-Jeong Lee
机构
[1] Chungnam National University,Department of Psychiatry, School of Medicine
[2] Sejong Chungnam National University Hospital,Department of Psychiatry
[3] Korea University Chronobiology Institute,Department of Biostatistics
[4] Korea University College of Medicine,Department of Psychiatry
[5] Korea University College of Medicine,undefined
来源
Scientific Reports | / 10卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
There have been concerns about abuse and unnecessary chronic administration of zolpidem, and zolpidem’s relation to suicide risk. To investigate the temporal association of zolpidem with the risk of suicide, we conducted a 12-year, population-based, retrospective cohort study on the National Health Insurance Service–National Sample Cohort (NHIS-NSC), South Korea. Data were collected from 2002 to 2013 from the NHIS-NSC, and data cleaning was performed for 1,125,691 subjects. Cox proportional hazards regression analysis was used to investigate the correlation over time between zolpidem medication and suicide. Over intervals commencing after 80 months of observation, the adjusted hazard ratio of suicides associated with the use of the zolpidem was 2.01 (95% CI: 1.58–2.56; p < 0.001). The mean cumulative number of days of zolpidem prescription was significantly longer in the suicide group than in the non-suicide group after log-transformation (p = 0.005). Cases of chronic use of zolpidem (over six months or one year) were significantly more common in the suicide group compared to the non-suicide group (p = 0.002 and 0.005, respectively). Subjects who received zolpidem medication had a significantly higher risk of suicide after at least 80 months of observation, suggesting a long-term increased suicide risk associated with insomnia exposed to zolpidem medication.
引用
收藏
相关论文
共 94 条
  • [1] Pavlova MK(2019)Sleep disorders Am. J. Med. 132 292-299
  • [2] Latreille V(2017)Insomnia heterogeneity: characteristics to consider for data-driven multivariate subtyping Sleep. Med. Rev. 36 71-81
  • [3] Benjamins JS(2011)Insomnia is a risk factor for suicide—What are the next steps? Sleep. 34 1149-1150
  • [4] McCall WV(2015)Health correlates of insomnia symptoms and comorbid mental disorders in a nationally representative sample of US adolescents Sleep. 38 197-204
  • [5] Blank M(2013)Longitudinal course of depression scores with and without insomnia in non-depressed individuals: a 6-year follow-up longitudinal study in a Korean cohort Sleep. 36 369-376
  • [6] Suh S(2014)Insomnia and risk of cardiovascular disease: a meta-analysis Eur. J. preventive cardiology 21 57-64
  • [7] Sofi F(2006)Psychological and behavioral treatment of insomnia: update of the recent evidence (1998–2004) Sleep. 29 1398-1414
  • [8] Morin CM(2018)Prescription drugs used in insomnia Sleep. Med. Clin. 13 169-182
  • [9] Dujardin S(2016)Pharmacologic treatment of insomnia disorder: an evidence report for a clinical practice guideline by the American College of Physicians Ann. Intern. Med. 165 103-112
  • [10] Pijpers A(2014)An update on zolpidem abuse and dependence J. addictive Dis. 33 15-23